Raymond S W Tsang1, Michelle Shuel1, Kathleen Whyte1, Linda Hoang2, Gregory Tyrrell3, Greg Horsman4, John Wylie5, Frances Jamieson6,7, Brigitte Lefebvre8, David Haldane9,10, Rita R Gad11, Gregory J German12, Robert Needle13. 1. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada. 2. BC Public Health Microbiology and Reference Laboratory, Vancouver, British Columbia, Canada. 3. Provincial Laboratory for Public Health, Edmonton, Alberta, Canada. 4. Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada. 5. Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada. 6. Public Health Ontario, Toronto, Ontario, Canada. 7. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 8. Laboratoire de santé publique du Québec, Institut National de santé publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada. 9. Nova Scotia Health Authority, Halifax, Nova Scotia, Canada. 10. Dalhousie University, Halifax, Nova Scotia, Canada. 11. Communicable Disease Control Unit, Department of Health, Government of New Brunswick, Fredericton, New Brunswick, Canada. 12. Department of Health, Government of Prince Edward Island, Charlottetown, Prince Edward Island, Canada. 13. Public Health Laboratory and Microbiology, Eastern Health, St John's, Newfoundland and Labrador, Canada.
Abstract
Background: Previously we studied the antibiotic susceptibility of invasive Haemophilus influenzae collected in Canada from 1990 to 2006 and characterized isolates by serotype, MLST and ftsI gene sequencing for significant PBP3 mutations. Objectives: To provide an update based on isolates collected from 2007 to 2014. Methods: A total of 882 case isolates were characterized by serotype using slide agglutination and PCR. MLST was carried out to determine ST. Isolates were tested for β-lactamase production, presence of significant PBP3 mutations and antibiotic susceptibility by disc diffusion against 14 antibiotics. MIC values of three antibiotics were determined for 316 isolates using microbroth dilution. Results: Non-typeable H. influenzae accounted for 54.6% of the isolates and 45.4% were serotypeable, predominantly type a (23.1%), type b (8.3%) and type f (10.8%). The overall rate of ampicillin resistance due to β-lactamase production was 16.4% and increased from 13.5% in 2007-10 to 19% in 2011-14. Significant PBP3 mutations were identified in 129 isolates (14.6%) with 23 (2.6%) also producing β-lactamase. MLST identified related STs (ST-136, ST-14 and ST-367) associated exclusively with genetically β-lactamase-negative, ampicillin-resistant isolates and confirmed previously reported associations between significant PBP3 mutations and ST. Conclusions: A significant increase in β-lactamase-producing isolates was observed from 2007 to 2014; the rate of significant PBP3 mutations has increased since previously reported and 52.5% of non-typeable H. influenzae now show resistance markers. Resistance to trimethoprim/sulfamethoxazole was common and no resistance to fluoroquinolones or third-generation cephalosporins was found.
Background: Previously we studied the antibiotic susceptibility of invasive Haemophilus influenzae collected in Canada from 1990 to 2006 and characterized isolates by serotype, MLST and ftsI gene sequencing for significant PBP3 mutations. Objectives: To provide an update based on isolates collected from 2007 to 2014. Methods: A total of 882 case isolates were characterized by serotype using slide agglutination and PCR. MLST was carried out to determine ST. Isolates were tested for β-lactamase production, presence of significant PBP3 mutations and antibiotic susceptibility by disc diffusion against 14 antibiotics. MIC values of three antibiotics were determined for 316 isolates using microbroth dilution. Results: Non-typeable H. influenzae accounted for 54.6% of the isolates and 45.4% were serotypeable, predominantly type a (23.1%), type b (8.3%) and type f (10.8%). The overall rate of ampicillin resistance due to β-lactamase production was 16.4% and increased from 13.5% in 2007-10 to 19% in 2011-14. Significant PBP3 mutations were identified in 129 isolates (14.6%) with 23 (2.6%) also producing β-lactamase. MLST identified related STs (ST-136, ST-14 and ST-367) associated exclusively with genetically β-lactamase-negative, ampicillin-resistant isolates and confirmed previously reported associations between significant PBP3 mutations and ST. Conclusions: A significant increase in β-lactamase-producing isolates was observed from 2007 to 2014; the rate of significant PBP3 mutations has increased since previously reported and 52.5% of non-typeable H. influenzae now show resistance markers. Resistance to trimethoprim/sulfamethoxazole was common and no resistance to fluoroquinolones or third-generation cephalosporins was found.
Authors: Emma Meats; Edward J Feil; Suzanna Stringer; Alison J Cody; Richard Goldstein; J Simon Kroll; Tanja Popovic; Brian G Spratt Journal: J Clin Microbiol Date: 2003-04 Impact factor: 5.948
Authors: D Skaare; I L Anthonisen; G Kahlmeter; E Matuschek; O B Natås; M Steinbakk; A Sundsfjord; B E Kristiansen Journal: Euro Surveill Date: 2014-12-11
Authors: Fredrik Resman; Mikael Ristovski; Arne Forsgren; Bertil Kaijser; Göran Kronvall; Patrik Medstrand; Eva Melander; Inga Odenholt; Kristian Riesbeck Journal: Antimicrob Agents Chemother Date: 2012-06-11 Impact factor: 5.191
Authors: Raymond S W Tsang; Michelle L Sill; Stuart J Skinner; Dennis K S Law; Jianwei Zhou; John Wylie Journal: Clin Infect Dis Date: 2007-05-02 Impact factor: 9.079
Authors: James P Watt; Lara J Wolfson; Katherine L O'Brien; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Orin S Levine; Rana Hajjeh; Kim Mulholland; Thomas Cherian Journal: Lancet Date: 2009-09-12 Impact factor: 79.321
Authors: Anna Carrera-Salinas; Aida González-Díaz; Laura Calatayud; Julieta Mercado-Maza; Carmen Puig; Dàmaris Berbel; Jordi Càmara; Fe Tubau; Imma Grau; M Ángeles Domínguez; Carmen Ardanuy; Sara Martí Journal: Microb Genom Date: 2021-12